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Abstract
With its alarmingly rising prevalence worldwide, type 2 diabetes has become a  
leading cause of morbidity and mortality around the planet. Efforts to prevent 
progression to diabetes in individuals at risk could have a significant positive 
public health impact. Multiple trials examining cardiovascular outcomes of Renin-
Angiotensin-Aldosterone System (RAAS) inhibitors revealed, in secondary analysis, 
a significantly reduced risk of new onset diabetes in participants receiving these 
agents. This glycemic protective effect is attributed to the known implication of 
RAAS in the development of insulin resistance and type 2 diabetes. The DREAM trial 
and the NAVIGATOR trial were two large randomized controlled studies examining, 
as primary outcome, the effect of Ramipril and Valsartan respectively on the inci-
dence of diabetes in patients with prediabetes. Their results confirmed a favorable 
glycemic effect of RAAS inhibition agents and suggested a possible added benefit of 
diabetes prevention to their other several cardiovascular and blood pressure benefits.
Keywords: diabetes prevention, renin-angiotensin- aldosterone system,  
glucose homeostasis, ACE inhibitors, angiotensin receptor blockers, prediabetes
1. Introduction
Diabetes Mellitus (DM) is a chronic disease characterized by hyperglycemia 
due to impaired glucose regulation [1]. Glucose regulation is controlled by insulin, 
a protein hormone produced and secreted by the 𝛃-cells of the pancreas. Type 2 
diabetes mellitus (T2DM) is characterized by insulin resistance and impaired 𝛃-cell 
function, eventually leading to decreased insulin secretion.
Prediabetes is the disease state which precedes the diagnosis of diabetes [2]. It is 
characterized by hyperglycemia caused by insulin resistance and 𝛃-cell dysfunction, 
as is type 2 diabetes, but before serum glucose levels reach that of diabetic diagnostic 
thresholds. Just as in diabetes, the diagnosis of prediabetes is made based on results 
of fasting plasma glucose, oral glucose tolerance test, Hemoglobin A1c, and/or 
random serum glucose levels [3]. Prediabetes can be defined by impaired fasting 
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glucose (IFG) with a fasting plasma glucose level 100–126 mg/dL (5.5–7.0 mmol/L), 
impaired glucose tolerance (IGT) with glucose level of 140–200 mg/dL  
(7.8–11.1 mmol/L) at 2 hours of the oral glucose tolerance test (OGTT), and/or 
HbA1c level of 5.7–6.5% (39–48 mmol/mol) [2, 3].
As the prevalence of diabetes continues to increase, it has become a severe 
public health problem worldwide. According to the World Health Organization 
(WHO) and International Diabetes Foundation (IDF), 451 million adults were 
diagnosed with diabetes worldwide in 2017, which was drastically increased from 
108 million in 1980 [2–4]. This number is expected to increase to 693 million by the 
year 2045 [3]. According to the CDC, in 2015, approximately half (48.3%) of the 
adult population ages 65 and older had prediabetes [2].
With its many microvascular and macrovascular complications, diabetes con-
tributes to a large portion of healthcare costs worldwide. In fact, approximately 850 
billion USD of the global healthcare expenditure was spent on patients with diabe-
tes in 2017 [2]. Research has shown that individuals with diabetes are at increased 
risk of cardiovascular disease (CVD), the leading cause of death worldwide [1]. The 
Framingham Heart study found that women with diabetes had a five times greater 
risk of heart failure, while men had two times greater risk, when compared to indi-
viduals of the same age and gender without diabetes [5]. Prediabetes has also been 
found to be independently associated with microvascular complications, macrovas-
cular complications (including CVD) and increased risk of overall mortality [6, 7].
Aside from the increased risk of CVD in individuals with diabetes, an indepen-
dent association between hypertension and insulin resistance has been established 
[8]. The Hong Kong Cardiovascular Risk Factor Prevalence Study found that of 
individuals with diabetes, 58% had elevated blood pressure, and of people with 
hypertension, 34% had impaired glucose tolerance. Only 42% of subjects stud-
ied with diabetes had normal blood pressure [9]. While the mechanism of this 
relationship is unclear, it has been hypothesized that patients with hypertension 
have impaired glucose tolerance due to changes in skeletal muscle tissue [10]. This 
common coexistence of hypertension and diabetes increases one’s risk of CVD 
and events, and thus contributes to the increased risk of morbidity and mortality 
in these patients. Both hypertension and insulin resistance are components of the 
cardiometabolic syndrome, a group of interrelated abnormalities, which increase 
the risk for CVD and T2DM. Other related abnormalities include obesity, left 
ventricular hypertrophy, dyslipidemia, and albuminuria [10, 11].
Given the increasing prevalence of diabetes worldwide and its many complica-
tions, a significant effort has been made to explore preventive modalities. Studies have 
concluded that lifestyle interventions involving diet and physical activity reduce the 
risk of diabetes by greater than 50% [12]. However, the intense lifestyle modifica-
tions necessary to result in change are often difficult to implement. Bariatric surgery 
has been found to be an effective method of diabetes prevention and treatment. In 
a meta-analysis of 22,094 patients who had undergone bariatric surgery, diabetes 
was completely resolved in 76.8% of patients [13]. The Swedish Obese Subject 
Study, a prospective study of 4047 patients without diabetes who underwent gastric 
surgery, found that after 15 years, 392 of 1658 control patients developed diabetes 
compared to 110 of 1771 patients who underwent bariatric surgery (p < 0.001) [14]. 
Pharmacological agents such as metformin, thiazolidinediones, alpha-glucosidase 
inhibitors, and the glucagon-like peptide-1 agonist, liraglutide have been shown to 
prevent diabetes in those at risk [1, 15]. However, none of these agents have the added 
benefit of hypertension or CVD prevention and/or treatment. In fact, thiazolidinedio-
nes have been associated with an increased risk of congestive heart failure [12].
Pharmacological agents which act by inhibition of the Renin-Angiotensin-











































DREAM 2006 IGT and/or IGF (5269) Ramipril Placebo Primary Non-significant decrease in new-onset DM (HR 0.91, 
95% CI 0.80–1.03), Significantly increased regression 
of IFG and IGT to normoglycemia, decrease in OGTT 
2 hr. glucose level.
NAVIGATOR 2008 IGT + > 50 y/o with CVD OR > 55 y/o 
with > 1 RF for CVD (9518)
Valsartan Placebo Primary significantly reduced DM incidence by 14% (HR 0.86, 
95% CI 0.80–0.92)
HOPE 2001 Multiple cardiovascular risk factors 
(9297)
Ramipril Placebo Secondary significantly reduced risk of new-onset DM (RR 0.66, 
95% CI 0.41–0.77)
CAPP 1999 Ages 25–66 with HTN (DBP > 
100 mmHg) (10,985)
Captopril diuretics and/or 
B-blocker
Secondary significantly decreased risk of new-onset DM with 
captopril by 14% (RR 0.86; 95% CI, 0.74–0.99)
ALLHAT 2002 Hypertension + 1 or more CHD 
Risk factor (MI, stroke, LVH, 




Secondary significantly decreased risk of new-onset DM among 
patients taking lisinopril (8.1%) vs. amlodipine (9.8%) 
and chlorthalidone (11.6%)
LIFE 2002 Ages 55–80, hypertension + left 
ventricular hypertrophy (9193)
Losartan Atenolol Secondary significantly decreased risk of new-onset DM in 
patients taking losartan compared with atenolol (HR 
0.75; 95% CI, 0.63–0.88; p < 0.001)
PEACE 2004 > 50 years, coronary heart disease 
with LVEF > 40% (8.290)
Trandolapril Placebo Secondary significantly decreased incidence of new onset DM 
in patients taking Trandolapril (HR 0.83; 95% CI, 
0.72–0.96; p=.01)
VALUE 2004 HTN and high CV risk (male, 
>50 years, DM, current smoker, high 
TC, LVH, proteinuria) (15,245)
Valsartan Amlodipine Secondary significantly decreased incidence of new-onset DM in 
patients taking Valsartan compared with Amlodipine 
(HR 0.77; 95% CI 0.69–0.86; p<.0001)
Table 1. 
Trials with diabetes prevention as a primary and secondary outcome of RAAS inhibition.
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(ACE-I) and angiotensin receptor blockers (ARBs) have been observed to have a 
favorable glycemic effect, and are among candidates examined in recent diabetes 
prevention trials. While they are often utilized for their blood pressure-lowering 
effect, they have cardiovascular benefits as well. Specifically, ACE-I have been 
found to play a role in the reversal of left ventricular hypertrophy in patients 
with hypertension, and preventing left ventricular remodeling post myocardial 
infarction [16]. Thus, ACE-I are indicated as first line agents in patients with heart 
failure, left ventricular systolic dysfunction (LVEF < 40–45%) and those with acute 
coronary syndrome and after suffering from an acute myocardial infarction [16]. 
In patients with heart failure, ACE-I have been shown to reduce mortality, hospi-
talizations, and prevent worsening of heart failure in these individuals [16]. The 
benefits of ARBs are less well defined, however, the clinical trial Val-HeFT found 
treatment with ARB, valsartan, resulted in decreased morbidity and mortality in 
patients with heart failure, when compared with placebo [17]. Additionally, ARBs 
have been found to slow the progression of diabetic nephropathy thus preventing 
end stage renal disease (ESRD) in these patients. Two trials, IDNT and RENAAL 
conducted in 2001, revealed ARBs (Irbesartan and Losartan) to be effective in 
reducing proteinuria and slowing the progression of ESRD in patients with diabetic 
nephropathy, independent of their blood-pressure lowering effect [18, 19].
Given these benefits, RAAS inhibitors are often first line agents for treating 
patients with concomitant hypertension and diabetes and those at risk for CVD. 
Several studies to date suggest that ACE-I and ARBs have the ability to improve gly-
cemic control by improving insulin sensitivity. Table 1 provides a brief description 
of the studies and their findings. This chapter explores the possibility of utilizing 
RAAS inhibitors as a means of diabetes prevention and/or improved glucose toler-
ance and the potential mechanisms by which this could be accomplished.
2. RAAS and glucose homeostasis
The renin-angiotensin-aldosterone system (RAAS) is responsible for regulating 
arterial blood pressure and blood volume [20, 21]. Renin, an enzyme produced 
by the juxtaglomerular cells in the kidney in response to low blood pressure or 
decreased sodium delivery to the kidneys, converts angiotensinogen to angiotensin 
I. Angiotensin converting enzyme (ACE), found in the lungs and kidneys, then 
converts angiotensin I to angiotensin II (AG II). Angiotensin II is the predominant 
hormone responsible for the hemodynamic effects of RAAS, namely: sodium 
retention at the proximal convoluted tubules of the kidneys, arterial vasoconstric-
tion, and release of aldosterone from the adrenal glands [22]. Angiotensin II is also 
responsible for the non-hemodynamic effect of RAAS related to glucose hemostasis 
[21, 23]. Several studies have suggested the role of RAAS in the development of 
insulin resistance and subsequent development of type 2 diabetes mellitus (T2DM) 
in humans. The pathophysiology is complex, mostly involving the skeletal muscle, 
adipose tissue, and pancreas [21] (Figure 1).
1. RAAS and the skeletal muscle: AG II affects glucose metabolism in the skeletal 
muscle through the inhibition of insulin-mediated glucose uptake and insulin 
signaling pathway, and a decrease in the blood supply to the skeletal muscle [21].
Inhibition of insulin-mediated glucose uptake and insulin signaling pathway. The 
skeletal muscle accounts for up to 70% of insulin-mediated glucose uptake in 
the body, which occurs through a series of tightly regulated events in the insulin 
signaling pathway [23, 24]. First, insulin binds to the insulin receptor on the 
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surface of the skeletal muscle cell, and this activates a cascade of events that 
ultimately ends in translocation of the glucose transporters (GLUT-4) from 
intracellular vesicles to the cell membrane through which glucose is taken up by 
the cells [23, 24]. Therefore, inhibition at any stage in the signaling pathway will 
result in insulin resistance with subsequent type 2 diabetes development if left 
unresolved. By acting through the angiotensin II type 1 receptor (AT1R), AG II 
activates NADPH oxidase, which leads to the production of reactive oxygen spe-
cies that in turn inhibits insulin-mediated translocation of GLUT-4 transporters, 
glucose uptake, and insulin signaling pathway in the skeletal muscle [23, 24].
Decrease in the blood supply to the skeletal muscle. Studies also show that AG II 
contributes to insulin resistance by decreasing microvascular blood supply to 
the skeletal muscle [21].
2. RAAS and the adipose tissue: Studies have shown that local RAAS present in 
adipose tissue affects adipocyte differentiation through angiotensin II’s action on 
its AT1R receptor [21], but there are conflicting views on the exact mechanism. 
For example, some studies suggest that AG II inhibits adipocyte precursor 
differentiation, thereby decreasing the number of insulin-sensitive adipocytes 
leading to insulin resistance [25]. In contrast, other studies indicate that AG II 
stimulates adipocyte differentiation and causes an increase in adipocyte size in 
visceral adipose tissue leading to obesity and insulin resistance [21].
3. RAAS and the pancreas: Increased activity of local pancreatic RAAS is asso-
ciated with impaired glucose metabolism. By acting through the AT1R recep-
tor, AG II decreases insulin secretion, impairs blood flow to the pancreatic 
islet cells, and causes inflammation and fibrosis of the pancreas, leading to 
impaired glucose tolerance [21].
In summary, through its different effects on the skeletal muscle, adipose tissue, 
and pancreas, RAAS is thought to contribute to the development of insulin resis-
tance and development of type 2 diabetes. Therapy with RAAS inhibitors has been 
Figure 1. 
Potential mechanisms implicated in favorable glycemic effect associated with RAAS inhibition.
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indeed associated with favorable glycemic events. At a clinical level, several trials 
have examined the role of RAAS inhibition in preventing the development of type 2 
diabetes in the population at risk.
3. Diabetes prevention as a secondary outcome of RAAS inhibition trials
There have been a number of trials conducted in which the primary aim was to 
study the effect of RAAS inhibitors on CVD and events. In addition to this primary 
outcome of interest, a number of these trials have found positive results with 
regards to their effect on diabetes prevention and improved glucose tolerance.
One of the first clinical trials to demonstrate a protective effect of RAAS inhibi-
tion on the incidence of diabetes was the Captopril Prevention Project (CAPPP) 
initiated in 1999. The primary aim of this trial was to compare the effect of ACE 
inhibition (using captopril) with conventional therapy (𝛃-blockers and/or diuret-
ics) on risk of CVD morbidity and mortality in patients with hypertension [26]. 
While there was no difference in prevention of cardiovascular morbidity and mor-
tality in those treated with captopril compared with conventional therapy, authors 
did find that the incidence of new onset diabetes was lower in participants treated 
with captopril [26]. This finding supports the theory that ACE inhibition may work 
to prevent the development of diabetes, which may be due to captopril’s ability 
to improve insulin sensitivity [26]. Additionally, those patients with diabetes at 
baseline who were treated with captopril had a lower rate of cardiovascular events 
and mortality when compared to those with diabetes treated with conventional 
therapy [26].
Another study, the Heart Outcomes Prevention Evaluation (HOPE) study, 
sought to explore the role of the ACE inhibitor, ramipril, on the incidence of 
myocardial infarction (MI), stroke, or all-cause mortality in patients with a history 
of vascular disease (coronary artery disease, stroke, peripheral vascular disease) or 
diabetes, plus at least one other cardiovascular risk factor (hypertension, elevated 
total cholesterol levels, low high-density lipoprotein cholesterol levels, cigarette 
smoking, or microalbuminuria), but without heart failure or any degree of left ven-
tricular dysfunction [27]. Subjects were randomized to receive ramipril or placebo, 
both with the addition of 400 IU of vitamin E daily [27]. Of the primary outcomes 
examined, patients treated with ramipril had a significantly decreased risk of myo-
cardial infarction, stroke, or death from cardiovascular causes (RR 0.78, 95% CI 
0.70–0.86). Of the participants without a diagnosis of diabetes at study onset, there 
was a 34% decreased incidence of new onset diabetes in those treated with ramipril 
compared with placebo (RR 0.66, 95% CI 0.34–0.76) [27]. Of note, these results are 
consistent with the study to Evaluate Carotid Ultrasound changes in patients treated 
with ramipril and vitamin E (SECURE), which reported decreased fasting glucose 
levels in patients treated with ramipril when compared with placebo [28].
Another trial, the Losartan Intervention For Endpoint reduction in hyperten-
sion study (LIFE), randomized participants aged 55–80 years with hypertension 
and electrocardiographic left ventricular hypertrophy (ECG LVH) to either 
losartan or atenolol [29]. The primary aim of this trial was to determine whether 
losartan improves LVH and thus reduces cardiovascular morbidity and mortality. 
Results revealed that those participants who received losartan had a decreased risk 
of cardiovascular events (MI and stroke), and 25% decreased risk of new onset 
DM when compared with atenolol (HR 0.75, 95% CI 0.63–0.88, p 0.001) [30]. It is 
possible that the protective effect of losartan on diabetes incidence seen in the LIFE 
trial could be due to the detrimental effects of atenolol, a 𝛃-blocker, on insulin 
sensitivity [10].
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The presence of diabetes has been found to be associated with increased left 
ventricular hypertrophy, both of which are risk factors for the cardiometabolic 
syndrome [29]. The initial analysis of the LIFE trial found that individuals treated 
with losartan had an increased regression of LVH when compared to those treated 
with atenolol. However, patients with diabetes and LVH had less regression than 
those without diabetes, possibly secondary to their predisposition [29]. A sec-
ondary analysis was conducted on the participants without diabetes at baseline, 
which sought to determine whether in-treatment resolution or continued absence 
of ECG LVH is associated with decreased risk of developing diabetes [29]. This 
analysis revealed a 38% decreased incidence of DM in those who had resolution or 
continued absence of LVH (HR 0.62, 95% CI 0.50–0.78, p < 0.001) independent 
of the previously identified effects of treatment with losartan versus atenolol. This 
finding suggests that while DM might lead to LVH, it is possible that LVH may in 
fact precede the development of diabetes [29]. While the causality of this relation-
ship is uncertain, this study proposes the idea that regression of LVH by means of 
RAAS inhibition might decrease the risk for DM. However, it is also possible that 
this observed relationship between LVH regression and decreased incidence of DM 
can be explained by the established association between hypertension and insulin 
resistance. This idea aligns with the finding that participants of the LIFE trial who 
developed diabetes had higher baseline systolic and diastolic blood pressures than 
those who did not [29].
In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack 
(ALLHAT) trial, the primary aim was to compare the effectiveness of treatment 
with diuretic, chlorthalidone against calcium channel blocker, amlodipine and 
ACE-I, lisinopril in preventing coronary heart disease (CHD) or other cardiovas-
cular events in patients with hypertension and at least one CHD risk factor [31]. As 
far as primary outcome of interest, chlorthalidone was found to be superior to the 
others in preventing the primary outcome. However, study participants on lisinopril 
were found to have a lower incidence of diabetes at the follow up period of four 
years, when compared to those placed on other antihypertensives [31].
Similarly, the Prevention of Events with Angiotensin Converting Enzyme 
Inhibition (PEACE) trial sought to determine whether treatment with another 
ACE-I, trandolapril in patients with stable CAD and left ventricular ejection frac-
tion (LVEF) > 40% would reduce cardiovascular deaths, incidence of MI or need 
for percutaneous coronary intervention (PCI) when compared with treatment 
with placebo [32]. Although a secondary end point, results from this trial revealed 
that the incidence of new onset DM was significantly decreased in those treated 
with trandolapril when compared to those in the placebo group (HR 0.83, 95%CI 
0.72–0.96, p=0.01) [32]. Results from the PEACE trial, similar to the HOPE trial are 
important because they cannot be attributed to the adverse effects of the compari-
son drug (placebo).
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial 
compared coronary heart disease outcomes in patients with hypertension treated 
with valsartan or amlodipine [33]. While there were no differences in primary 
composite outcome of cardiovascular morbidity and mortality in either group, sec-
ondary analysis revealed that new-onset DM occurred significantly less in patients 
treated with valsartan [33]. Despite the observed decreased incidence of diabetes 
with valsartan use, blood pressure reduction was less in this group, compared to 
those treated with amlodipine, which suggests that the effect of ARBs on diabetes 
prevention is independent of blood pressure reduction [34].
While each of the above trials found treatment with ACE-I and ARBs to be 
associated with decreased incidence of new onset diabetes, it must be noted that 
diabetes prevention was not a defined primary outcome in any of these studies. 
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Thus, their results must be interpreted with caution. A few other weaknesses 
should be taken into consideration on review. Some of these trials, including 
the HOPE and PEACE trials did not perform formal glucose testing to establish 
glycemic status, and relied on self-report alone [32, 35, 36]. Additionally, the 
HOPE, CAPP, and LIFE trials all utilized 𝛃-blockers as comparator drugs, which 
allows for the possibility that the observed effect of therapy with ACE-I or ARB on 
diabetes prevention is due to the detrimental effects of B-blockers on development 
of diabetes rather than the benefits of RAAS inhibition. A large prospective cohort 
study (n=12,550) conducted in 2000 revealed that hypertensive patients taking 
𝛃-blockers had a 28% increased risk of diabetes when compared to those who were 
not on any antihypertensive therapy [37].
4. DREAM and NAVIGATOR trials
Studies including the aforementioned trials showed a beneficial effect of RAAS 
inhibition with ACE-I and ARBs on diabetes prevention among patients with 
hypertension and other cardiovascular diseases [30, 35, 38, 39]. These trials studied 
diabetes prevention as a secondary outcome or post hoc analysis, thus the results 
should be interpreted with caution. Conversely, the DREAM and NAVIGATOR 
trials, conducted in 2006 and 2008, respectively, are double blind, randomized 
clinical trials, which were designed to determine the effect of RAAS inhibition on 
the incidence of diabetes as a primary outcome [40, 41]. Furthermore, in these two 
trials, glycemic categories were meticulously determined, defined and recorded. In 
both studies, DM was defined using standard criteria, fasting blood glucose (FBG) 
126 mg/dl or 200 mg/dl post oral glucose load and confirmed again at a later date. 
In the DREAM study, even in the event that diabetes was diagnosed by an outside 
physician, confirmation of the diagnosis using standard plasma glucose criteria was 
required in addition to the prescription of an antidiabetic agent by the diagnosing 
physician [40].
The DREAM trial was designed to investigate the effect of ramipril, an ACE-I 
and rosiglitazone, a thiazolidinedione, on diabetes prevention among patients with 
prediabetes (IGT and/or IFG) but without cardiovascular disease. The primary 
outcome of this study was newly diagnosed diabetes or death, with a secondary 
outcome of regression to normoglycemia defined as normal fasting and 2 hour 
post-load glucose levels [40]. Data analysis revealed no significant difference in the 
development of diabetes in the ramipril group when compared to the placebo group 
(HR 0.91, 95% CI 0.80–1.03) [40]. However, the likelihood of regression to normo-
glycemia was increased among subjects within the ramipril group when compared 
to the placebo group (HR 1.16, 95% CI 1.07–1.27). Moreover, while the fasting 
plasma glucose levels did not differ between the ramipril and the placebo group at 
the end of the trial, the 2 hour post glucose oral load values were significantly lower 
among those within the ramipril group [40].
There are a number of possible explanations for the lack of reduction in DM 
incidence with ramipril use in the DREAM trial which was different from the results 
found in previous trials with ACE-I/ARBs. First, as mentioned, diagnosis of diabe-
tes at study onset was unambiguously established in participants of the DREAM 
trial with an oral glucose tolerance test (OGTT), thus patients with pre-existing 
DM were reliably excluded from the study [40]. This was not the case for some of 
the other studies mentioned previously [35, 42]. Second, the demographics of the 
DREAM study patients differed from those of trials which showed a reduced inci-
dence of DM with RAAS inhibitors. Compared to the participants of the DREAM 
trial, subjects from the other trials were older, and had established CVD, and/or 
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heart failure [30, 35, 36, 43, 44]. It is possible that the RAAS system is activated to a 
greater extent and thus ACE inhibition may have greater benefits in these individu-
als [45]. Third, some of the trials that revealed reduced incidence of DM among 
those treated with ACE-I/ARBs had compared ACE-I with other anti-hypertensives 
associated with dysglycemia, such as 𝛃-blockers, as mentioned previously. This 
may have led to a possible exaggeration of the effect of RAAS inhibition on diabetes 
prevention. Fourth, most of the previous trials that showed a beneficial effect of 
ACE-I And ARB on DM prevention followed the patients for longer period of time 
than the median 3 years that the participants of the DREAM trial were followed for 
[30, 32, 35, 39, 43]. Specifically, the participants of the HOPE trial were followed for 
4.5 years, the PEACE trial for 4.8 years, ALLHAT study for 4.9 years, and the LIFE 
study for 4.8 years [30, 32, 35, 39]. In the DREAM trial, there was a late diversion 
of the Kaplan–Meier curves that suggested a benefit of ramipril in DM prevention 
after 3–5 years. Thus, it is possible that a longer and larger study may be needed to 
observe the effect of ramipril on DM prevention [45].
Four years after the publication of the results of the DREAM trial, the results 
of another trial, the Nateglinide and Valsartan in Impaired Glucose Tolerance 
Outcomes Research (NAVIGATOR) trial, were released [41]. This study also sought 
to investigate the effect of RAAS inhibition with the ARB, valsartan in addition 
to lifestyle modification on diabetes prevention in patients with impaired glucose 
tolerance and established CVD or CVD risk factors.
The NAVIGATOR trial was an improvement over the DREAM trial in several 
ways. First, a study-specific lifestyle-intervention program, which has previ-
ously been found to reduce risk of diabetes by up to 50%, was implemented for 
all patients in addition to pharmacotherapy [46, 47]. Second, there was a longer 
median follow up of 5 years in the NAVIGATOR trial compared with the 3 years 
follow up in the DREAM trial [40, 41]. Third, the NAVIGATOR trial enrolled a 
larger number of participants, 9306, versus 5269 participants in the DREAM trial. 
Another difference between these studies is that, unlike the DREAM trial, the 
NAVIGATOR trial enrolled patients with established CVD or CVD risk factors, who 
may have a greater degree of RAAS activation at baseline.
With these differences in mind, it is not surprising that while the DREAM 
trial found no difference between the ramipril and placebo groups with regards to 
diabetes prevention, the NAVIGATOR trial found that those treated with valsartan 
had a significantly reduced incidence of DM by 14% (HR 0.86, 95% CI 0.80–0.92, 
p< 0.001). Furthermore, patients in the valsartan arm of the study had lower 
mean fasting plasma glucose and 2 hours post glucose load levels. Additionally, the 
proportion of patients taking glucose lowering agents at the end of the study was 
lower in the valsartan group than in those in the placebo group.
Although significant, the 14% reduction in diabetes risk with valsartan appears 
smaller than the risk reduction seen in previously conducted trials involving ACE-I 
and ARBs [32, 35, 36, 44, 48]. One possible reason is that by the last study visit, a 
significantly higher proportion of subjects in the placebo arm were taking other 
ARBs or ACE-I (24.4% vs. 21.8%), which could have diluted the effect seen with 
valsartan. Another reason for this observed discrepancy could be due to a difference 
in the way in which glycemic status was determined at study onset and completion. 
Unlike the NAVIGATOR trial, a few other trials diagnosed DM by self-report rather 
than formal glucose testing which allows for misclassification error and possible 
false exaggeration of results [35].
In addition, the effect of valsartan with lifestyle modification was much smaller 
compared to landmark studies on diabetes prevention with lifestyle alone in which 
the incidence of DM was reduced by as much as 58% [46, 47, 49]. Similarly, the 
effect of valsartan on diabetes prevention in the NAVIGATOR trial is smaller when 
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compared to glucose lowering agents such as metformin, 26–31% [46, 50], acarbose 
25% [51] and rosiglitazone 60% in the DREAM study [52]. It is worthy of note that 
the NAVIGATOR trial followed the subjects for a longer duration (5 years) com-
pared to the trials involving these glucose lowering agents in which subjects were 
followed for 2.5–3.3 years.
In conclusion, the DREAM and NAVIGATOR trials showed benefit in glycemic 
indices but only the NAVIGATOR trial showed a reduced diabetes incidence as a 
primary outcome of RAAS inhibition with ACE-I and ARBs. These findings may 
have utility in the clinical setting, in terms of choice of antihypertensive agents to 
those at higher risk of DM development, in the presence or absence of CVD and its 
risk factors.
5. Conclusion and clinical implications
ACE-I and ARBs are currently widely used for the treatment of patients with 
hypertension, heart failure or asymptomatic left ventricular dysfunction, coronary 
artery disease, and diabetic nephropathy, with the clinical benefits of ACE-I more 
closely studied [53]. Based on the results from the aforementioned trials, the use 
of these agents may also be indicated for the prevention of diabetes and/or regres-
sion from impaired to normoglycemia. This is extremely significant in light of the 
emerging diabetes epidemic.
While it is not entirely clear, results from the trials explored throughout this 
chapter suggest that those with cardiometabolic syndrome and its risk factors 
including (but not limited to) hypertension, obesity, insulin resistance, and left 
ventricular hypertrophy may experience the greatest benefits with regards to diabe-
tes prevention and improved glycemic control. This could be due to the fact that the 
RAAS system is overactive in a number of these conditions. As discussed, activation 
of the RAAS system and increased production of angiotensin II is thought to play a 
role in the development of insulin resistance and subsequent development of T2DM 
[21]. It is also possible that the ability of ACE-I and ARBs to prevent diabetes is in 
part due to their effect on blood pressure reduction and LVH regression, both of 
which have been shown to improve insulin sensitivity [29].
However, while results from the CAPPP trial found a decreased incidence of new 
onset DM in patients treated with captopril, the blood pressure of patients in this 
group was significantly higher throughout the study than those treated with con-
ventional therapy with 𝛃-blocker and/or diuretics. This supports the hypothesis that 
captopril’s effect on diabetes prevention might be independent of blood pressure 
reduction. Results from the sub-analysis of the LIFE trial suggests that the effect 
of RAAS inhibition with losartan on LVH regression may be partly responsible for 
the decreased incidence of DM. It is possible that this association is also explained 
in part by the relationship between blood pressure and insulin resistance [29]. In 
conclusion, the apparent decreased incidence of new onset diabetes seen in patients 
treated with ACE-I and ARBs are likely attributable to both direct and indirect 
effects of these agents.
Given the variety of indications for which RAAS inhibitors have been estab-
lished, the additional benefit of diabetes prevention could help to alleviate 
polypharmacy in individuals who suffer from several of these conditions simultane-
ously. However, more research is needed to categorically place ACE-I and ARBs 
among the armamentarium of agents favoring DM prevention. Head to head studies 
comparing the effects of different ACE-I and ARBs would also be useful.
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